Inflammation, Epigenetics in CHF Patients With AF

University of Palermo164 enrolled

Overview

the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF * The serum levels of some candidate cytokine variables and their relationship with some selected metabolic variables and some echocardiographic variables. * the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation and the related cardiac remodelling. * to analyze the correlation between selected miRNA and the selected cytokines.

Study Type

OBSERVATIONAL

Enrollment

164

Conditions

Congestive Heart Failure Chronic Atrial Fibrillation (Permanent)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * ≥18 years * Left ventricular ejection fraction \>40% * New York Heart Association class II-IV symptoms * NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography Exclusion Criteria \- Other AF subtypes (paroxysmal, persistent, long-standing persistent) At least one of the following criteria: * Acute heart failure * NYHA IV * NT-proBNP \>4000 pg/mL * Significant valvular disease * Mechanical prosthesis * Cardiovascular implantable devices * Active malignancy * Inflammatory or infectious diseases * Severe renal (eGFR \<30 mL/min/m²) or hepatic failure * Chronic steroid/anti-inflammatory therapy

Locations (1)

Internal Medicine and Stroke Care Ward, Policlinic Hospital of Palermo, Sicily

Palermo, PA, Italy

Outcomes

Primary Outcomes

inflammation and structural cardiac remodelling

in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml) and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain %

Time frame: From January 2020 to May 2022

Secondary Outcomes

epigenetic alterations and cardiac remodelling

in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain %

Time frame: From January 2020 to May 2022

inflammation and epigenetic alterations

in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a blood sample for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml)

Time frame: From January 2020 to May 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.